Securities Purchase Agreement

Amendment No. 1 to Securities Purchase Agreement

 
Exhibit 4.105

 


 
AMENDMENT NO. 1, dated as of December 2, 2009 (this “Amendment”), to the Securities Purchase Agreement, dated as of October 12, 2009 (the “SPA”), among Amarin Corporation plc, a company incorporated under the laws of England and Wales (the “Company”) and the purchasers listed on Exhibit A thereto (each, a “Purchaser” and collectively, the “Purchasers”).  Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the SPA.
 
WHEREAS, Section 10.5 of the SPA permits the SPA to be amended from time to time;
 
NOW, THEREFORE, in consideration of the premises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:
 
Section 1. Amendments.
 
As of the date hereof, the SPA shall be amended as follows:
 
(a) Article 8 of the SPA is hereby amended by adding the following definition:
 
Specified Shares” means any Ordinary Shares: (A) acquired by the Lead Investors under the 2008 Investors SPA; (B) acquired by the purchasers under the 2008 Directors SPA; (C) issuable upon exercise of the warrants (i) granted to Thomas Lynch pursuant to resolutions adopted by the Board of Directors of the Company on October 16, 2009, (ii) granted to Alan Cooke pursuant to the Compromise Agreement dated October 16, 2009 between him and the Company and (iii) that may be granted to Tom Maher pursuant to a Compromise Agreement between him and the Company; and (D) issuable upon exercise of the “Warrants” granted pursuant to, and as such term is defined in, the Securities Purchase Agreement, dated as of December 16, 2005, among the Company and the purchasers party thereto.
 
(b) Section 6.1(b) of the SPA is hereby replaced in its entirety with the following:
 
(b)           The Company’s shareholders shall not have the right to include in the Registration Statement any of the Company’s securities other than Registrable Securities and the Specified Shares.

 
 

 


Section 2. Effectiveness.
 
This Amendment will become effective upon the execution hereof by the Company and (A) Purchasers holding the number of Ordinary Shares required for the amendments to the SPA set forth herein to be effective and (B) Holders holding the number of Registrable Securities required for the amendment to Article 6 of the SPA set forth herein to be effective, in each case as provided in Section 10.5 of the SPA.
 
Section 3. Counterparts.
 
This Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which when so executed and delivered shall be deemed to be an original, but all of which when taken together shall constitute a single instrument.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile transmission shall be effective as delivery of a manually executed counterpart hereof.
 
Section 4. Applicable Law. 
 
THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT WOULD PRODUCE A CONTRARY RESULT.
 
Section 5. Headings.
 
The headings of this Amendment are for purposes of reference only and shall not limit or otherwise affect the meaning hereof.
 
Section 6. Effect of Amendment.
 
Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of or otherwise affect the rights and remedies of the Purchasers or the Holders under the SPA, and shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the SPA or any other provision of the SPA, all of which are ratified and affirmed in all respects and shall continue in full force and effect.
 

[Signature page follows.]

 
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first above written.
 

Purchasers:

Caduceus Private Investments III, LP
By:  OrbiMed Capital GP III LLC, its General Partner
 
By:  /s/ Carl L. Gordon      
        Name:  Carl L. Gordon
        Title:    Partner
 
OrbiMed Associates III, LP
By:  OrbiMed Advisers LLC, its General Partner
 
By:  /s/ Carl L. Gordon      
        Name:  Carl L. Gordon
        Title:    Partner
 
Sofinnova Venture Partners VII, L.P.
By:  Sofinnova Management VII, L.L.C., its General Partner
 
By:  /s/ James I. Healy      
        Name:  James I. Healy
        Title: Managing General Partner
 
Longitude Venture Partners, L.P.
By:  Longitude Capital Partners, LLC, its General Partner
 
By:  /s/ Patrick Enright      
        Name:  Patrick Enright
        Title: Managing Member
 
Longitude Capital Associates, L.P.
By:  Longitude Capital Partners, LLC, its General Partner
 
By:  /s/ Patrick Enright      
        Name:  Patrick Enright
        Title: Managing Member

 
 

 




Fountain Healthcare Partners Fund 1, L.P.
By:  Fountain Healthcare Partners Ltd., its General Partner
 
By:  /s/ Manus Rogan      
        Name:  Manus Rogan
        Title: Managing Partner
 
Stichting Depositary APG Developed Markets Equity Pool
 
 
By:  /s/ R.M. Stam      
        Name:  R.M. Stam
        Title:    Authorized signatory
 
By:  /s/ R.J. Douma      
       Name:  R.J. Douma
       Title:    Authorized signatory
 
Abingworth Bioventures V L.P.
By:  Abingworth LLP, its Manager
 
By:  /s/ James Abell      
       Name:  James Abell
       Title: Partner
 
Abingworth Bioventures V Co-Invest Growth Equity Fund L.P.
By:  Abingworth LLP, its Manager
 
By:  /s/ James Abell      
        Name:  James Abell
        Title: Partner
 
Abingworth Bioventures Master Fund Limited
 
 
By:  /s/ James Abell      
        Name:  James Abell
        Title: Authorised Signatory

 
 

 




Biomedical Offshore Value Fund, Ltd.
By:  Great Point Partners, LLC, its Investment Manager
 
By:  /s/ Jeffrey R. Jay      
        Name:  Jeffrey R. Jay
        Title: Senior Managing Member
 
Biomedical Value Fund, L.P.
By:  Great Point Partners, LLC, its General Partner
 
By:  /s/ Jeffrey R. Jay      
        Name:  Jeffrey R. Jay
        Title: Senior Managing Member
 
Visium Balanced Master Fund, Ltd.
 
 
By:  /s/ Mark Gottlieb      
        Name:  Mark Gottlieb
        Title: Signatory
 
Opus Point Healthcare Innovations Fund, L.P.
 
 
By:  __________________________________
        Name:  Michael S. Weiss
        Title: Manager of the Investment Manager
 
Opus Point Healthcare Value Fund, L.P.
 
 
By:  _________________________________
        Name:  Michael S. Weiss
        Title: Manager of the Investment Manager
 
Opus Point Healthcare (Low Net) Fund, L.P.
 
 
By:  _________________________________
        Name:  Michael S. Weiss
        Title: Manager of the Investment Manager

 
 

 


Opus Point Capital Preservation Fund, L.P.
 
 
By: _________________________________
        Name:  Michael S. Weiss
        Title: Manager of the Investment Manager
 
Capital Ventures International
 
 
By:  _________________________________
        Name:  Martin Kobinger
        Title: Investment Manager
 
Cummings Bay Capital
 
 
By:  _________________________________
        Name:  Michael Gregory
        Title: Authorised Person
 
Geneve Corp.
 
 
By:  _________________________________
        Name:  Michael Gregory
        Title: Authorised Person
 
BioHedge Holdings Limited
 
 
By:  _________________________________
        Name:  Steven Salmon
        Title: President, Rosalind Advisors, Inc.
 
Rosalind Capital Partners, L.P.
 
 
By:  _________________________________
        Name:  Steven Salmon
        Title: President, Rosalind Advisors, Inc.
 
 

 
 

 



Boxer Capital LLC
 
 
By:  /s/ Chris Fuglesang      
        Name:  Chris Fuglesang
        Title: Member, Counsel
 
RCG PB Ltd.
 
 
By:  _________________________________
        Name:  Jeffrey C. Smith
        Title: Authorized Signatory
 
Ramius Enterprise Master Fund Ltd.
 
 
By:  _________________________________
        Name:  Jeffrey C. Smith
        Title: Authorized Signatory
 
RA Capital Healthcare Fund, L.P.
 
 
By:  _________________________________
        Name:  Peter Kolchinsky
        Title: Manager
 
Blackwell Partners, LLC
 
 
By:  _________________________________
        Name:  Peter Kolchinsky
        Title: Manager
 
Sunninghill Limited
 
 
By:  _________________________________
        Name:
        Title: Director
 
By:  _________________________________
        Name:
        Title: Director

 
 

 



Midsummer Ventures, LP
 
 
By:  _________________________________
        Name:  Michael Amsalem
        Title: President of General Partner,
                  Midsummer Advisors
 
Midsummer Investment, Limited
 
 
By:  _________________________________
        Name:  Michael Amsalem
        Title: Director
 
 
/s/ David Brabazon      
David Brabazon
 
/s/ David Hurley        
David Hurley
 
____________________________ 
Thomas G. Lynch
 
/s/ Simon Kukes      
Dr. Simon Kukes
 
/s/ Eunan Maguire      
Eunan Maguire
 
/s/ Anthony Russell Roberts   
Anthony Russell Roberts


 
 

 


AMARIN CORPORATION PLC

By:       /s/ Conor Dalton
Name:  Conor Dalton
Title:    Vice President Finance and
             Principal Accounting Officer